[Predictive molecular pathological stratification of hematological neoplasms]

Area of Science:

• Hematology
• Oncology
• Molecular Biology

Background:

• Genomic sequencing reveals heterogeneity and potential therapeutic targets in hematological neoplasms.
• Current targeted therapies primarily focus on protein targets, which are not directly detectable by nucleic acid methods.
• Protein-level analysis offers insights into target expression and signaling pathways in tumor cells.

Purpose of the Study:

• To investigate the diagnostic utility of protein-specific antibodies in hematological neoplasms.
• To highlight the importance of tissue-based protein diagnostics for patient selection in targeted therapy.
• To assess the contribution of these methods to the predictive diagnostics of multiple myeloma.

Main Methods:

• Utilizing immunohistochemistry with mutation, phosphorylation, and glycosylation-specific primary antibodies.
• Analyzing protein expression and alterations in signal cascades within tumor cells.
• Evaluating diagnostic applications for various hematological neoplasms.

Main Results:

• Demonstrated the diagnostic value of protein-level investigations in hematological malignancies.
• Confirmed the suitability of immunohistochemistry for identifying therapeutic targets.
• Showcased significant contributions to the predictive diagnostics of multiple myeloma.

Conclusions:

• Tissue-based protein diagnostics are essential for effective patient selection in targeted cancer therapy.
• Immunohistochemistry provides critical information for identifying actionable protein targets in hematological neoplasms.
• This approach significantly enhances the predictive diagnostics for multiple myeloma and other related cancers.